Your concierge patients pay for a report that takes hours to assemble by hand. CellWise turns one PBMC sample into an immune-age, senescence, and 12-Hallmarks profile: white-labeled, drafted automatically, and defensible against a sector full of unvalidated protocols.
The work that scales worst with a premium roster, handled.
Aggregating genomics, lipid panels, CGM, DEXA, and wearables into a custom longevity report is hours of physician time each visit. CellWise auto-drafts a white-labeled report from a single PBMC sample.
Longevity is crowded with protocols that carry credibility and liability risk. CellWise anchors your read in three peer-reviewed frameworks: sc-ImmuAging, the 125-gene SenMayo panel, and the 12 Hallmarks of Aging.
Compliance slips without objective feedback. Longitudinal re-screens and assay-independent surveillance give patients a visible, molecular reason to stay the course.
The clinical home base. Use-case assessments, immuno-metabolic phenotyping, the therapeutic target map, stress profiling, and more, all in one report.
The quantitative, visual view of the patient's raw biomarker data, shown as a population-vs-patient overview.
A filterable, gene-level interface over the patient's complete dataset, exposing the top cell populations carrying each signal.
Test a clinical hypothesis against the patient's own molecular data and re-run it in seconds.
Assay-independent surveillance across dosing phases, peptide-specific labs, and wearable trends, with no repeat sequence required.
Immune age, senescence, and the 12 hallmarks from one PBMC sample, for cell-resolved biological aging.
Re-assay a patient and see the gene-expression deltas across key biomarkers, so you see what has shifted since the last screen.
Reviewers converged on the same aging signal and the same intervention plan from a single sample, with no manual synthesis.
The convergence of TLR9, IRF7, TLR7, and IFNG into a coherent narrative would take me 45–60 minutes to synthesize from raw scRNA-seq. The platform delivers it in a structured card.
A validated immune-age read from three peer-reviewed frameworks is exactly the credibility anchor this sector is missing.
Being able to simulate rapamycin against the patient’s actual expression before I write the plan changes the conversation in the room.
Join the founding pilot: up to five of your own patients at $1,485 each, 29% below the standard rate, invoiced only for the ones you send. Founding rates lock for twelve months if you go forward, and every pilot practice is a design partner with a say on what gets built. Open to a limited cohort of concierge and longevity practices.